Boston Scientific Closes NxThera Acquisition

Boston Scientific Corporation has today announced its acquisition of NxThera, the company that developed the Rezūm® system.

NxThera will become part of the Boston Scientific Urology and Pelvic Health business, which provides a range of treatments for both men and women’s urological and gynaecological conditions. The rezum system will complement the company’s existing portfolio of treatment options.

Boston Scientific Executive Vice present Dave Pierce commented: “We are confident in the potential for this system to help patients with BPH and increase the number of men choosing MITs, because it offers long-term relief from symptoms without the side effects of medications. The minimally invasive therapy segment is the fastest growing category in the treatment of BPH and, as an office-based procedure, the Rezūm system is appealing to patients, clinicians and payers.”